DEBRISOQUIN SULFATE
| Title | Journal |
|---|---|
| The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1. | Biochemical pharmacology 20120515 |
| CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans. | The pharmacogenomics journal 20120401 |
| Debrisoquine metabolism and CYP2D expression in marmoset liver microsomes. | Drug metabolism and disposition: the biological fate of chemicals 20120101 |
| Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. | Bioorganic & medicinal chemistry letters 20101101 |
| Extrapolating in vitro metabolic interactions to isolated perfused liver: predictions of metabolic interactions between R-bufuralol, bunitrolol, and debrisoquine. | Journal of pharmaceutical sciences 20101001 |
| Assessment of chimeric mice with humanized liver as a tool for predicting circulating human metabolites. | Drug metabolism and pharmacokinetics 20100101 |
| Sympathetic activation in chronic renal failure. | Journal of the American Society of Nephrology : JASN 20090501 |
| Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. | Pharmacogenomics 20090101 |
| Complementary DNA cloning, functional expression and characterization of a novel cytochrome P450, CYP2D50, from equine liver. | Biochemical pharmacology 20081001 |
| Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers. | Pharmacogenomics 20080701 |
| Chimeric mice with humanized liver. | Toxicology 20080403 |
| The effect of a long term epidural infusion of ropivacaine on CYP2D6 activity. | Anesthesia and analgesia 20080101 |
| Metabolism of antidepressant and neuroleptic drugs by cytochrome p450s: clinical and interethnic aspects. | Clinical pharmacology and therapeutics 20071101 |
| Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. | Drug metabolism and disposition: the biological fate of chemicals 20070801 |
| No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients. | European journal of clinical pharmacology 20070501 |
| Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. | European journal of clinical pharmacology 20070401 |
| In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver. | Journal of pharmaceutical sciences 20070201 |
| Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the 'cocktail' approach. | Clinical pharmacology and therapeutics 20070201 |
| Genotyping of the cytochrome P450 2D6 4469 C>T polymorphism using SimpleProbes. | Scandinavian journal of clinical and laboratory investigation 20070101 |
| 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio. | Drug metabolism and disposition: the biological fate of chemicals 20060901 |
| Liver disease selectively modulates cytochrome P450--mediated metabolism. | Clinical pharmacology and therapeutics 20060901 |
| Validation of incorporating flurbiprofen into the Pittsburgh cocktail. | Clinical pharmacology and therapeutics 20060901 |
| Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo. | European journal of clinical pharmacology 20060701 |
| Influence of chronic renal failure on stereoselective metoprolol metabolism in hypertensive patients. | Journal of clinical pharmacology 20051201 |
| Metabolism of N-hydroxyguanidines (N-hydroxydebrisoquine) in human and porcine hepatocytes: reduction and formation of glucuronides. | Drug metabolism and disposition: the biological fate of chemicals 20051001 |
| Cytochrome P450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction. | European journal of clinical pharmacology 20050901 |
| Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution. | Proteins 20050501 |
| Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship. | Clinical chemistry and laboratory medicine 20050101 |
| Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH. | Journal of clinical pharmacology 20041201 |
| The roles of amino acid residues at positions 43 and 45 in microsomal contents and enzymatic functions of rat CYP2D1 and CYP2D2. | Biochemical and biophysical research communications 20041112 |
| In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. | Clinical pharmacology and therapeutics 20041101 |
| Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients. | Pharmacopsychiatry 20040301 |
| Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1. | British journal of clinical pharmacology 20040201 |
| Altered distribution of the debrisoquine oxidative phenotypes in children with type 1 diabetes mellitus. | Hormone research 20040101 |
| [CYP 2D6 activity profile among patients with depression]. | Psychiatria polska 20040101 |
| The hepatic and intestinal metabolic activities of P450 in rats with surgery- and drug-induced renal dysfunction. | Pharmaceutical research 20031001 |
| Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine. | European journal of clinical pharmacology 20030901 |
| Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians. | British journal of clinical pharmacology 20030601 |
| Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. | European journal of clinical pharmacology 20030501 |
| Coordinated intrahepatic and extrahepatic regulation of cytochrome p4502D6 in healthy subjects and in patients after liver transplantation. | Clinical pharmacology and therapeutics 20030501 |
| Interaction of serum proteins with CYP isoforms in human liver microsomes: inhibitory effects of human and bovine albumin, alpha-globulins, alpha-1-acid glycoproteins and gamma-globulins on CYP2C19 and CYP2D6. | Life sciences 20030314 |
| Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. | Clinical pharmacology and therapeutics 20030301 |
| QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. | Journal of psychopharmacology (Oxford, England) 20021201 |
| Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate? | Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20021101 |
| New allelic arrangement CYP2D6*36 x 2 found in a Japanese poor metabolizer of debrisoquine. | Pharmacogenetics 20021101 |
| Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients. | Journal of clinical psychopharmacology 20021001 |
| Is cytochrome P450 CYP2D activity present in pig liver? | Pharmacology & toxicology 20021001 |
| Catalytic specificity of CYP2D isoforms in rat and human. | Drug metabolism and disposition: the biological fate of chemicals 20020901 |
| 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine. | The Journal of pharmacology and experimental therapeutics 20020601 |
| QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy. | European journal of clinical pharmacology 20020601 |
| Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine. | Drug metabolism and disposition: the biological fate of chemicals 20020501 |
| Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). | Clinical pharmacology and therapeutics 20020301 |
| Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects. | British journal of clinical pharmacology 20020201 |
| The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity. | Clinical pharmacology and therapeutics 20020101 |
| Effects of terfenadine and diphenhydramine on the CYP2D6 activity in healthy volunteers. | European journal of drug metabolism and pharmacokinetics 20020101 |
| [Prevalence of ultraextensive drug metabolizers in Croatian population--long-PCR based detection of amplified CYP2D6 gene]. | Lijecnicki vjesnik 20020101 |
| The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. | Molecular pharmacology 20011201 |
| Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes. | Therapeutic drug monitoring 20011201 |
| The Paton Prize Award. The discovery of the debrisoquine hydroxylation polymorphism: scientific and clinical impact and consequences. | Toxicology 20011101 |
| An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). | British journal of clinical pharmacology 20011101 |
| Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. | Clinical pharmacology and therapeutics 20011001 |
| Heterogeneity of the CYP2D6 gene among Malays in Malaysia. | Journal of clinical pharmacy and therapeutics 20010601 |
| Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6. | The Biochemical journal 20010415 |
| Moving toward genetic profiling in patient care: the scope and rationale of pharmacogenetic/ecogenetic investigation. | Drug metabolism and disposition: the biological fate of chemicals 20010401 |
| Interaction of plasma proteins with cytochromes P450 mediated metabolic reactions: inhibition by human serum albumin and alpha-globulins of the debrisoquine 4-hydroxylation (CYP2D) in liver microsomes of human, hamster and rat. | Toxicology letters 20010308 |
| Characterization of stereoselectivity and genetic polymorphism of the debrisoquine hydroxylation in man via analysis of urinary debrisoquine and 4-hydroxydebrisoquine by capillary electrophoresis. | Electrophoresis 19970901 |
| Cyclophosphamide-induced acute liver failure requiring transplantation in a patient with genetically deficient debrisoquine metabolism: a causal relationship? | Journal of internal medicine 19961101 |
| Thalidomide-induced neuropathy and genetic differences in drug metabolism. | European journal of clinical pharmacology 19950101 |
| Genetically determined drug-metabolizing activity and desipramine-associated cardiotoxicity: a case report. | Clinical pharmacology and therapeutics 19930101 |
| Perhexiline maleate-induced hepatitis. | Hepato-gastroenterology 19910801 |
| Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers. | The Journal of pharmacology and experimental therapeutics 19910301 |
| Lack of defect in oxidative hydroxylation of debrisoquine in a patient with halothane hepatitis. | European journal of clinical pharmacology 19900101 |
| Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation. | Gastroenterology 19830901 |
| Prediction of subclinical perhexiline neuropathy in a patient with inborn error of debrisoquine hydroxylation. | American heart journal 19830101 |
| Psychiatric side effects of antihypertensive drugs other than reserpine. | Journal of clinical psychopharmacology 19820201 |
| Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. | British medical journal (Clinical research ed.) 19820130 |
| Patterns of blood-pressure during chronic administration of postganglionic sympathetic blocking drugs for hypertension. | Lancet (London, England) 19761113 |
| Exertional hypotension due to postganglionic sympathetic blocking drugs. | Postgraduate medical journal 19760801 |
| Factors predisposing to postural hypotensive symptoms in the treatment of high blood pressure. | British heart journal 19751001 |